Navigation Links
MDS Appoints Two New Directors
Date:4/21/2008

Gregory Spivy and William Dempsey join MDS Board

TORONTO, April 21 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that Mr. Gregory Spivy, Partner at ValueAct Capital, and Mr. William Dempsey, former Executive Vice-President of Abbott Laboratories, have been appointed to its Board of Directors.

"We welcome both Greg and Bill and look forward to benefiting from the breadth of experience they will bring to our Board," said John Mayberry, Chairman, MDS Board of Directors. "The decision of both individuals to join the Board follows months of discussion and is consistent with our objective to strengthen and broaden the Board's expertise."

Mr. Mayberry continued, "Greg adds the perspective of a major shareholder with financial markets expertise, along with the knowledge and experience of having served on the boards of other publicly traded companies. Bill is an industry veteran and possesses the operational skills, knowledge and perspective of our customers that come from more than 25 years of pharmaceutical industry experience. We believe that the capabilities of both individuals will be additive and prove valuable to the Board as we continue to execute on our strategy to deliver value to all of our shareholders."

"MDS has built a strong position in the global life science markets and has developed a solid foundation upon which to generate sustainable and profitable growth," stated Mr. Spivy. "I believe there is growth potential in the MDS markets and I look forward to working actively with my fellow directors and MDS's management team to capitalize on these opportunities."

"I am pleased to be joining the MDS Board of Directors," stated Mr. Dempsey. "This is an excellent company with a history of innovation, quality products and services, and a leadership team driving performance."

Mr. Spivy is a Partner at ValueAct Capital, a San Francisco-based investment partnership with approximately $6 billion in assets under management. ValueAct Capital is currently MDS's largest shareholder, owning approximately 19% of the Company's outstanding Common shares. Mr. Spivy currently serves on the board of directors of Adesa Holdings, Inc. and Seitel Holdings, Inc., and serves as Chairman of the Board of MSD Performance, Inc. He is also a former director of PRA International, MSC.Software Corporation and Kerr Group, Inc. As a member of the MDS Board of Directors, Mr. Spivy will serve on the Corporate Governance and Nominating Committee, and the Human Resources & Compensation Committee.

Mr. Dempsey has spent nearly his entire career with Abbott Laboratories, serving most recently as Executive Vice-President of the Pharmaceutical Products Group. In his more than 25 years of experience with Abbott, Mr. Dempsey served in a variety of roles across their pharmaceuticals, nutritionals, medical devices and hospital businesses. Mr. Dempsey will serve on the Audit Committee and the Environment, Health and Safety Committee.

In connection with Mr. Spivy's appointment to the Board, MDS entered into an agreement with ValueAct Capital that is filed with the Canadian and US Securities regulators, and will be available through the SEDAR and EDGAR websites.

About MDS

MDS is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

About ValueAct Capital

ValueAct Capital(R), with offices in San Francisco and Boston and approximately $6 billion in investments, seeks to make active strategic-block value investments in a limited number of companies. The Principals have demonstrated expertise in sourcing investments in companies they believe to be fundamentally undervalued, and then working with management and/or the company's board to implement strategies that generate superior returns on invested capital. ValueAct Capital concentrates primarily on acquiring significant ownership stakes in publicly traded companies, and a select number of control investments, through both open-market purchases and negotiated transactions.


'/>"/>
SOURCE MDS Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MaxLife Fund Corp. Appoints Mr. Dan Schmitt, Mr. Randy Delkus and Mr. Daniel E. Kahan to its Board of Directors
2. Bioniche Appoints U.S. President of Food Safety
3. WellPoint Appoints Kevin R. Hayden as President of State Sponsored Business
4. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
5. ProGenTech Limited Appoints Executive Management Team
6. Precyse Solutions Appoints Karen Heisler as New Corporate Vice President, Human Resources
7. Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer
8. Optimal Readings Appoints Operations Veteran Rita Edwards as SVP Clinical Operations
9. Stiefel Laboratories Appoints First Chief Scientific Officer
10. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
11. Prevent Child Abuse Georgia Appoints New CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Public middle and high ... to apply for a 2016/2017 California Casualty Thomas R. Brown Athletics Grant. The ... can receive up to $3,000. , The grant is named after California ...
(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... thrilled to formally announce its Not a Moment to Lose fundraising campaign. As ... rally supporters dedicated to declaring victory over cancer. The campaign aims to raise ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... is now offering HIAC particle counting and sizing services for USP 788 and ... instituted the new service as a response to the needs of pharmaceutical and ...
(Date:12/6/2016)... ... 2016 , ... METTLER TOLEDO has launched its online ... papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user manuals, ... webinars and videos available online, visit the METTLER TOLEDO Expertise Library . ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 2016   Mallinckrodt Pharmaceuticals (NYSE: ... announced that it received a perfect score of 100 ... national benchmarking survey and report on corporate policies and ... workplace equality, administered by the Human Rights Campaign (HRC) ... businesses which also earned top marks this year. ...
(Date:12/5/2016)... Dec. 5, 2016 ... antibiotics have emerged as a crucial class of ... In addition, antibiotics are also used for prophylactic ... immunocompromised patients (cancer patients undergoing chemotherapy). However, the ... food production, has rapidly accelerated an evolutionary response ...
(Date:12/5/2016)... 5, 2016 Special purpose needles are used in ... fluid and cells from organs or lumps and are available ... The global market for special purpose needles is showing a ... of revenue, the global special purpose needles market is projected ... period (2016–2026) and is expected to be valued at US$ ...
Breaking Medicine Technology: